Last Updated: October, 2026
Trusted by 200+ Clients
The report provides detailed analysis essential for establishing an idelalisib production plant. It encompasses all critical aspects necessary for idelalisib production, including the cost of idelalisib production, idelalisib plant cost, idelalisib production costs, and the overall idelalisib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an idelalisib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Idelalisib is an oral small-molecule cancer drug that blocks the delta form of phosphatidylinositol 3-kinase, known as PI3K delta. Gilead Sciences sells it as Zydelig, and it was the first PI3K delta inhibitor approved for blood cancers. Approval came in the US and the EU in 2014. PI3K delta signaling drives the growth, survival, homing, and retention of malignant B cells in lymph nodes and bone marrow. Blocking it slows chronic lymphocytic leukemia, follicular lymphoma, and related B-cell cancers. Patients take a single 150 mg tablet twice a day until the disease progresses or side effects become too severe.
Demand for idelalisib is small, specialist, and shrinking in most markets. The US label now covers only relapsed chronic lymphocytic leukemia, given with rituximab. Gilead withdrew the accelerated approvals for follicular lymphoma and small lymphocytic lymphoma. In the EU, the drug remains approved for chronic lymphocytic leukemia with an anti-CD20 antibody and for refractory follicular lymphoma. Newer drugs, which are safer, easier to use, and backed by stronger trial data, have taken most of its patients. BTK inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib now lead treatment, along with venetoclax. Idelalisib is kept for patients who cannot take those drugs or whose disease has stopped responding to them.
Idelalisib supply is limited and is influenced more by patents than by production capacity. Gilead remains the original developer and a major supplier in the US, EU, UK, Australia, and other regulated markets. Patents covering certain polymorphic forms of idelalisib extend to 2033 in the US. Natco Pharma filed an ANDA and faced a lawsuit from Gilead in Delaware before reaching a confidential settlement. A consent judgment restricted Natco’s US sales to the terms of the settlement. Natco already sells a branded generic called Ideenat 150 in India, where 30 tablets have a printed price of about ?17,800. PharmaCompass lists three US DMFs and about nine API suppliers. Idelalisib demand and supply depend on patient numbers, patent expiry dates, label restrictions, and the rate at which BTK inhibitors are adopted.
Idelalisib has the molecular formula C22H18FN7O, a molar mass of 415.42 g/mol, and the CAS number 870281-82-6. Its chemical name is 5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]quinazolin-4(3H)-one. The molecule joins a fluorinated quinazolinone core to an adenine-type purine through a chiral aminopropyl link. Only the S isomer is active, so chiral purity is a release test, a stability test, and a key process control. It is a white to off-white solid that is stored at room temperature, protected from moisture, and shipped in sealed containers. Solubility depends strongly on pH, below 0.1 mg/mL at pH 5 to 7 and above 1 mg/mL at pH 2. Polymorph control matters, since the crystal forms are patented.
Idelalisib is sold in three main grades, each for different buyers and uses. Pharmaceutical API grade is produced under GMP for tablet manufacturers and is supported by DMFs or ASMFs. Research grade is used by cancer biology labs, immunology groups, screening centers, and CROs to study PI3K delta activity. Reference standards and impurity standards are used by quality control labs, analytical method developers, and companies filing ANDAs.
Each API lot is tested for assay, related substances, the R enantiomer, polymorphic form, particle size, water, and residual solvents. Elemental impurities and a des-fluoro impurity also get close attention. Finished Zydelig tablets come in 100 mg and 150 mg film-coated strengths. Excipients include microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, sodium starch glycolate, and magnesium stearate. The film coat adds polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, and a color.
Relapsed chronic lymphocytic leukemia is the main use of idelalisib. It is used in hematology clinics, cancer centers, specialty pharmacies, and hospital oncology units. Doctors give it with rituximab to patients whose disease has returned after earlier treatment. In the US, it is also approved for patients who could normally receive rituximab alone because of other health conditions. Treatment is continuous, so a patient uses about 110 g of API per year at the full dose. However, many patients stop treatment early because of liver, gut, lung, skin, or infection-related side effects. As a result, actual API use per patient is often lower than the amount based on the full labeled dose.
Follicular lymphoma is the second end-use in Europe and some other markets, for disease refractory to two earlier lines. Use there is now small, scattered, and mostly limited to patients with few other options. Several other lymphoma drugs, including bispecific antibodies, CAR-T cell therapies, lenalidomide combinations, and tazemetostat, compete for the same patients. In the US, this indication is gone. Small lymphocytic lymphoma use has fallen away for the same reason.
Research and analytical uses make up the rest of demand, through universities, drug discovery groups, CROs, and generic developers. Cancer labs use idelalisib to study PI3K delta signaling in B cells and immune cells. Generic developers buy reference material, impurity standards, enantiomer standards, and polymorph samples for method validation. These buyers order milligrams to grams. Their demand is steady, global, and diverse, but tiny in tonnage.
Idelalisib faces safety, competition, and patent risks that limit its market. Its US label has a boxed warning for serious and potentially fatal side effects. Clinical trials reported liver toxicity in 16% of patients, severe diarrhea or colitis in 20%, pneumonitis in 4%, and infections in 48%. Intestinal perforation, severe skin reactions, and allergic reactions have also been reported. Patients may need Pneumocystis prophylaxis, cytomegalovirus monitoring, liver tests, and close monitoring for diarrhea, cough, or fever. These safety concerns can lead doctors to choose BTK and BCL-2 inhibitors instead. Other PI3K delta drugs, such as umbralisib, have also been withdrawn from the market because of safety concerns. The smaller patient population can also make generic entry less attractive.
Idelalisib manufacturing has challenges related to chirality, polymorph control, potency, and its long production process. The chiral center can change during coupling and ring closure, so the R isomer must be kept at very low levels. Some reducing agents can remove fluorine from the ring and form a des-fluoro impurity that is difficult to remove. The multi-step process has moderate overall yields, so material losses in the later stages can be costly. Since idelalisib is a potent oncology compound, manufacturers use closed equipment, local exhaust systems, air locks, protective clothing, and other operator safety measures. Batches may fail because of high enantiomer levels, related impurities, incorrect polymorph form, or excess residual solvents.
The idelalisib production process runs from 2-fluoro-6-nitrobenzoic acid and aniline through amide formation, nitro reduction, coupling with Boc-L-2-aminobutyric acid, deprotection, purine coupling, quinazolinone ring closure, crystallization to the required polymorph, drying, and milling.
Idelalisib production starts with 2-fluoro-6-nitrobenzoic acid, a fluorinated aromatic intermediate. In a route published by Laurus Labs, the acid is converted to its acid chloride with oxalyl chloride. Condensation with aniline in 1,4-dioxane at 0 to 5 degree Celsius gives the N-phenyl nitrobenzamide in 86% yield and 99% purity. Zinc powder and ammonium formate then reduce the nitro group to an amine at room temperature, in 90% yield. Earlier palladium hydrogenation removed some fluorine and created des-fluoro impurities. Zinc reduction avoids that problem, uses cheap reagents, runs at room temperature, and needs no pressure equipment.
The amine is coupled with Boc-L-2-aminobutyric acid using CDI and HOBt in toluene at 8 to 15 degree Celsius for 30 to 32 hours. The yield at this step is 67%, with racemization kept below 1%. Trifluoroacetic acid in dichloromethane removes the Boc group, and the free amine is then neutralized, washed, and concentrated. The free amine reacts with 6-chloropurine, using zinc chloride and diisopropylethylamine in acetonitrile, at 80 to 100 degree Celsius for 10 to 12 hours. Hexamethyldisilazane and zinc chloride in refluxing acetonitrile then close the quinazolinone ring in about four hours. That final step gives idelalisib in 60% yield and 99.9% purity. Iodine-based ring closure caused about 50% racemization, so the zinc chloride method was a real gain. The full route gave about 21% overall yield, with chemical purity above 99%, at batch sizes of 150 to 190 g, which is a fair base for scale-up. Crystallization to the approved polymorph, drying, and milling finish the API. Route yield, chiral purity, cycle time, and the price of the chiral amino acid set most of the conversion cost.
Idelalisib production cost is shaped mainly by route yield and chiral raw materials. By stoichiometry, each kilogram of idelalisib needs about 0.45 kg of 2-fluoro-6-nitrobenzoic acid, 0.49 kg of Boc-L-2-aminobutyric acid, and 0.37 kg of 6-chloropurine. At an overall yield near 21%, the real use of the first intermediate is several times higher. Boc-L-2-aminobutyric acid is a chiral amino acid derivative and one of the costliest inputs. 6-chloropurine and the fluoronitrobenzoic acid come from specialty fine chemical makers. Coupling agents such as CDI and HOBt add steady cost, since they are used in excess, cannot be recovered, and add to waste. Solvents, zinc salts, and silylating agents are smaller items.
Long production times, containment, testing, and small batch sizes also add to idelalisib production costs. Coupling steps can take 10 to 32 hours, keeping reactors, workers, utilities, and production space occupied. Handling potent compounds requires closed transfer systems, isolators for charging and sampling, and special cleaning validation. Quality testing includes HPLC for assay and impurities, chiral HPLC, XRPD for polymorphs, water content, residual solvents, and elemental impurities. Global annual demand for idelalisib is small, possibly only a few hundred kilograms. As a result, fixed costs are spread across a limited number of batches. A single failed batch can reduce a large part of the annual profit.
Raw material sourcing for idelalisib centers on four intermediates: 2-fluoro-6-nitrobenzoic acid, aniline, Boc-L-2-aminobutyric acid, and 6-chloropurine. Chinese and Indian fine chemical makers supply most fluoroaromatic and purine intermediates. Boc-L-2-aminobutyric acid comes from amino acid and peptide building block producers. Its chiral purity, assay, water content, and residual solvents must all meet tight limits. Aniline is a bulk chemical, widely traded, cheap, and easy to buy. Coupling agents, zinc salts, hexamethyldisilazane, and solvents come from regular chemical distributors.
Input quality decides chiral purity, impurity levels, yield, and color. Boc-L-2-aminobutyric acid must be low in the D isomer, since any D content carries through to the R enantiomer of idelalisib. The fluoronitrobenzoic acid must be low in positional isomers and des-fluoro analogs. 6-chloropurine must be low in hypoxanthine and other purine impurities. Contracts for idelalisib inputs set limits for assay, related substances, chiral purity, water, and residual solvents. Each lot is sampled, quarantined, tested, and held until QC release. Suppliers are audited on site, by questionnaire, or through third parties before approval. Change notices trigger fresh testing and sometimes new process validation. A second approved source for the chiral amino acid protects campaigns from supply gaps.
Idelalisib manufacture raises environmental duties around solvents, zinc waste, fluorinated residues, and potent compound emissions. Dichloromethane, 1,4-dioxane, and acetonitrile need recovery, closed handling, or licensed disposal. Zinc salts from reduction and ring closure must be removed from wastewater by precipitation, filtration, or ion exchange before discharge. Trifluoroacetic acid and fluorinated byproducts are persistent and need careful treatment. Air extraction from potent compound areas passes through HEPA filters. Solvent recovery for toluene, acetonitrile, dichloromethane, and methanol cuts both waste and cost.
Idelalisib regulations are strict because it is a prescription cancer drug with a boxed warning. In the US, API manufacturers file DMFs, while finished drugs are approved through NDAs or ANDAs. In the EU, Gilead Sciences Ireland holds the marketing authorization, which was granted in September 2014. Generic manufacturers can use ASMF or CEP routes. The EU has placed idelalisib under additional monitoring and requires Pneumocystis prophylaxis during treatment and for up to six months after treatment. Manufacturers follow ICH Q7 for API production, ICH Q3A and Q3C for impurities and solvents, and ICH M7 for mutagenic impurities. Companies must also check polymorph and process patents before launching a generic product. Product labels include warnings about liver toxicity, diarrhea, colitis, pneumonitis, infections, and intestinal perforation.
An idelalisib plant is a small multi-purpose API facility designed to handle potent compounds safely. The plant setup cost includes glass-lined and stainless-steel reactors for acylation, reduction, coupling, deprotection, and ring closure. Nutsche filters or agitated filter dryers are used for filtration, while crystallizers provide close temperature control during polymorph formation. The plant also needs split butterfly valves, isolators for charging and sampling, and HEPA-filtered exhaust systems for containment. Milling and blending areas require dust control and operator protection. Utilities include chilled brine, steam, nitrogen, vacuum, solvent recovery, and effluent treatment systems. The quality control laboratory needs HPLC, chiral HPLC, GC, XRPD, Karl Fischer, ICP-MS, and particle size analysis equipment.
Idelalisib production costs mainly depend on chiral raw materials, labor, quality testing, and containment costs. Specialty intermediates, coupling agents, and solvents add regular variable costs. Long reaction times and moderate yields at each step increase labor costs per kilogram. Fixed costs include depreciation of contained production areas, cleaning validation, and quality systems. Producing idelalisib in the same plant as other oncology APIs, such as kinase inhibitors, antimetabolites, and hormonal agents, can reduce the cost per kilogram. Careful production planning can also reduce equipment changeover and cleaning time.
A suitable idelalisib plant should be located in an area with other oncology API manufacturers and easy access to fluorinated and chiral intermediates. In India, major production areas include Hyderabad, Visakhapatnam, and Gujarat, where companies such as Natco, Laurus Labs, and other oncology API manufacturers operate. China’s fine chemical clusters in Zhejiang, Jiangsu, and Shandong supply many of the required intermediates. Europe and the US have the main originator supply chain and contract manufacturers with facilities for handling potent compounds. A good plant location should have experience with FDA and EU inspections, skilled chemists, strong containment systems, and solvent recovery facilities.
For an idelalisib project, the first investment decision is timing against patents. US polymorph patents run to 2033, while other markets may open earlier. The second decision is scope, covering API only, API with tablets, or contract supply. A small contained API suite can serve several generic tablet makers, while an integrated API and tablet plant captures more value but needs more capital. Product range is the third decision. A stand-alone idelalisib unit would not pay back. Idelalisib therefore works best as one product in a multi-purpose oncology plant.
The US and Europe have the main originator supply chain through Gilead Sciences and its contract manufacturers. India is the main source of generic idelalisib, with Natco Pharma holding a US DMF and selling Ideenat in India. Laurus Labs has developed a scalable production process and has oncology API production capacity, process chemistry teams, contained production areas, and FDA-inspected sites. China supplies key intermediates and some research-grade API through companies such as Ningbo Inno Pharmchem. US distributors such as LGM Pharma supply API to drug developers and generic manufacturers. Reference standard companies such as Clearsynth supply materials for quality control and ANDA filings. Latin America, the Middle East, and Southeast Asia mainly import finished idelalisib tablets.
Gilead Sciences
Natco Pharma
Laurus Labs
LGM Pharma
Clearsynth
Ningbo Inno Pharmchem
Idelalisib Production Cost Report
Choose What's Right for You
Pay Via
| Particulars | Details |
|---|---|
| Product Name | Idelalisib |
| Scope | Production Process: Process Flow, Material Flow, Material Balance Raw Material and Product Specifications: Raw Material Consumption, Product and Co-product Generation Land and Site Cost: Offsites/Civil Works, Equipment Cost, Auxiliary Equipment Costs, Contingency, Engineering and Consulting Charges, Working Capital Variable Cost: Raw Material, Utilities, Other Variable Costs Fixed Cost: Labor Requirements and Wages, Overhead Expenses, Maintenance Charges, Other Fixed Costs Financing Costs: Interest on Working Capital, Interest on Loans Other Costs: Depreciation Charges, General Sales and Admin Cost |
| Currency | US$ (Data can also be provided in the local currency) | Customization Scope | The report can be customized as per the requirement of the customer |
| Post-Sale Analysts Report | 10-12 weeks of post-purchase analyst support after report delivery for any queries from the deliverable |
| Delivery Format | PDF and Excel format through email (editable version in PPT/Word format of the report can be also provided on special request) |
At Procurement Resource, we focus on improving the should-cost of production for idelalisib and map every stage of the route, from 2-fluoro-6-nitrobenzoic acid and aniline receipt through acid chloride formation and amidation, zinc and ammonium formate nitro reduction, CDI and HOBt coupling with Boc-L-2-aminobutyric acid, Boc deprotection, zinc chloride catalyzed coupling with 6-chloropurine, hexamethyldisilazane and zinc chloride ring closure, polymorph crystallization, drying, and milling. The cost model resolves each input separately, including 2-fluoro-6-nitrobenzoic acid, aniline, oxalyl chloride, zinc powder, ammonium formate, Boc-L-2-aminobutyric acid, CDI, HOBt, trifluoroacetic acid, 6-chloropurine, zinc chloride, diisopropylethylamine, hexamethyldisilazane, solvents, utilities, containment, labor, chiral and achiral HPLC, XRPD testing, packaging, and freight. We evaluate CAPEX and OPEX as cost per kilogram of idelalisib API and per tablet, isolating the chiral raw material share, the synthesis and yield share, and the containment and quality share, since these items set most of the delivered cost.
Alongside the cost build-up, the report identifies technology providers for chiral amide coupling, purine chemistry, quinazolinone ring closure, and potent compound containment, and offers a supplier database for fluoroaromatic intermediates, Boc-L-2-aminobutyric acid, 6-chloropurine, coupling agents, and solvents. It sets out a feasible plant layout covering raw material stores, contained reaction bays, filtration and drying, the crystallization suite, milling, QC laboratories, solvent recovery, and effluent treatment. By modeling step yields, chiral purity, intermediate prices, batch success rates, and plant utilization, the analysis shows where the cash production cost can be reduced. It supports decisions on route selection, making or buying intermediates, stand-alone versus multi-product plants, site location in Indian, Chinese, or Western clusters, and patent timing for US, EU, and other markets.
Lead - Social & Development Research
Delivering procurement intelligence and supply chain analytics across healthcare, FMCG, and chemicals sectors, with expertise in cost modeling, vendor mapping, and spend optimization to support data-driven sourcing decisions and procurement outcomes.
Need more help?
Still Need Help?
Compare & Choose the Right Report Version for You
How to Order Your Report?
